EZH2 and acute myeloid leukemia: This has fueled efforts for their integration into combination therapies (Kim et al., 2013) since combining EZH2 inhibitors with other therapeutics, such as the pan-histone deacetylase inhibitor panobinostat (Fiskus et al., 2009), 5-Azacytidine (Momparler et al., 2012), the BCL-2 inhibitor Venetoclax (Yang et al., 2022), FLT3 inhibitors (Sung et al., 2024), doxorubicin (Porazzi et al., 2022), Ara-C (Fujita et al., 2018) and ATRA (Sbirkov et al., 2023), can improve the efficacy of AML treatment and overcome the limitations of monotherapy.